Ovoca Bio PLC
LSE:OVB
Ovoca Bio PLC
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.